TRiCares

Executive Summary

TRiCares is a privately held medical device company headquartered in Munich, Germany, dedicated to developing a novel transcatheter solution for tricuspid regurgitation (TR), a serious and often underdiagnosed cardiac condition. TR affects millions worldwide and is associated with significant morbidity and mortality, yet treatment options remain limited due to the complex anatomy of the tricuspid valve and high surgical risk in many patients. TRiCares aims to address this unmet need with its proprietary minimally invasive implant designed to restore valve function without open-heart surgery. The company's technology targets the growing interventional cardiology market and has the potential to become a standard-of-care for inoperable or high-risk TR patients. Although still in the development stage, TRiCares has garnered interest from the medical community and investors owing to the strong clinical rationale and the massive commercial opportunity in the tricuspid valve space.

Upcoming Catalysts (preview)

• Q1 2026Completion of First-in-Human Study Enrollment80% success
• Q4 2026CE Mark Application Submission70% success
• Q3 2026Series B/C Funding Round Closing75% success